Cytochrome P450 architecture and cysteine nucleophile placement impact raloxifene-mediated mechanism-based inactivation

Molecular Pharmacology

Volumn 82, Issue 5, 2012, Pages 835-842

  VandenBrink, Brooke M ^a   Davis, John A ^a   Pearson, Josh T ^a   Foti, Robert S ^a   Wienkers, Larry C ^a   Rock, Dan A ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A5; GLUTATHIONE; RALOXIFENE;

ARTICLE; DRUG MECHANISM; ENZYME ACTIVE SITE; ENZYME INACTIVATION; ENZYME METABOLISM; ENZYME SUBSTRATE; IN VITRO STUDY; KINETICS; NUCLEOPHILICITY; PRIORITY JOURNAL; PROTEIN DEGRADATION;

CATALYTIC DOMAIN; COMPUTER SIMULATION; CYSTEINE; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME ACTIVATION; KINETICS; MODELS, MOLECULAR; RALOXIFENE;

EID: 84867779013     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.112.080739     Document Type: Article

References (47)

1. Baer BR, Wienkers LC, and Rock DA (2007) Time-dependent inactivation of P450 3A4 by raloxifene: identification of Cys239 as the site of apoprotein alkylation. Chem Res Toxicol 20:954-964. (Pubitemid 47035350)
2. Baillie TA, Pearson PG, Rashed MS, and Howald WN (1989) The use of mass spectrometry in the study of chemically-reactive drug metabolites. Application of MS/MS and LC/MS to the analysis of glutathione- and related S-linked conjugates of N-methylformamide. J Pharm Biomed Anal 7:1351-1360. (Pubitemid 20253557)
3. Bateman KP, Baker J, Wilke M, Lee J, Leriche T, Seto C, Day S, Chauret N, Ouellet M, and Nicoll-Griffith DA (2004) Detection of covalent adducts to cytochrome P450 3A4 using liquid chromatography mass spectrometry. Chem Res Toxicol 17:1356-1361. (Pubitemid 39391213)
4. Chan WK, Sui Z, and Ortiz de Montellano PR (1993) Determinants of protein modification versus heme alkylation: inactivation of cytochrome P450 1A1 by 1-ethynylpyrene and phenylacetylene. Chem Res Toxicol 6:38-45. (Pubitemid 23040370)
5. Chen Q, Ngui JS, Doss GA, Wang RW, Cai X, DiNinno FP, Blizzard TA, Hammond ML, Stearns RA, Evans DC, et al. (2002) Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation. Chem Res Toxicol 15:907-914. (Pubitemid 34774444)
6. Claiborne A, Mallett TC, Yeh JI, Luba J, and Parsonage D (2001) Structural, redox, and mechanistic parameters for cysteine-sulfenic acid function in catalysis and regulation. Adv Protein Chem 58:215-276. (Pubitemid 32954368)
7. Dahlin DC, Miwa GT, Lu AY, and Nelson SD (1984) N-acetyl-p-benzoquinone imine: a cytochrome P-450-mediated oxidation product of acetaminophen. Proc Natl Acad Sci USA 81:1327-1331. (Pubitemid 14173462)
8. Dickmann LJ, VandenBrink BM, and Lin YS (2012) In vitro hepatotoxicity and cytochrome P450 induction and inhibition characteristics of carnosic acid, a dietary supplement with antiadipogenic properties. Drug Metab Dispos 40:1263-1267.
9. Dieckhaus CM, Fernández-Metzler CL, King R, Krolikowski PH, and Baillie TA (2005) Negative ion tandem mass spectrometry for the detection of glutathione conjugates. Chem Res Toxicol 18:630-638. (Pubitemid 40563277)
10. Dong D and Wu B (2012) Substrate selectivity of drug-metabolizing cytochrome P450s predicted from crystal structures and in silico modeling. Drug Metab Rev 44:1-17.
11. Ferrer-Sueta G, Manta B, Botti H, Radi R, Trujillo M, and Denicola A (2011) Factors affecting protein thiol reactivity and specificity in peroxide reduction. Chem Res Toxicol 24:434-450.
12. Guengerich FP (2001) Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol 14:611-650.
13. Halpert JR (2011) Structure and function of cytochromes P450 2B: from mechanism-based inactivators to X-ray crystal structures and back. Drug Metab Dispos 39:1113-1121.
14. Hanson KL, VandenBrink BM, Babu KN, Allen KE, Nelson WL, and Kunze KL (2010) Sequential metabolism of secondary alkyl amines to metabolic-intermediate complexes: opposing roles for the secondary hydroxylamine and primary amine metabolites of desipramine, (s)-fluoxetine, and N-desmethyldiltiazem. Drug Metab Dispos 38:963-972.
15. Henne KR, Tran TB, VandenBrink BM, Rock DA, Aidasani DK, Subramanian R, Mason AK, Stresser DM, Teffera Y, Wong SG, et al. (2012) Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme. Drug Metab Dispos 40:1429-1440.
16. Hutzler JM, Steenwyk RC, Smith EB, Walker GS, and Wienkers LC (2004) Mechanism-based inactivation of cytochrome P450 2D6 by 1-[(2-ethyl-4-methyl-1H- imidazol-5-yl)methyl]-4-[4-(trifluoromethyl)-2-pyridinyl]piperazine: kinetic characterization and evidence for apoprotein adduction. Chem Res Toxicol 17:174-184. (Pubitemid 38252497)
17. Johnson EF and Stout CD (2005) Structural diversity of human xenobioticmetabolizing cytochrome P450 monooxygenases. Biochem Biophys Res Commun 338:331-336. (Pubitemid 41540575)
18. Kalgutkar AS and Didiuk MT (2009) Structural alerts, reactive metabolites, and protein covalent binding: how reliable are these attributes as predictors of drug toxicity? Chem Biodivers 6:2115-2137.
19. Kalgutkar AS, Obach RS, and Maurer TS (2007) Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions. Curr Drug Metab 8:407-447. (Pubitemid 47603408)
20. Kang P, Liao M, Wester MR, Leeder JS, Pearce RE, and Correia MA (2008) CYP3A4-Mediated carbamazepine (CBZ) metabolism: formation of a covalent CBZ-CYP3A4 adduct and alteration of the enzyme kinetic profile. Drug Metab Dispos 36:490-499. (Pubitemid 351409335)
21. Kemp DC, Fan PW, and Stevens JC (2002) Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance. Drug Metab Dispos 30:694-700. (Pubitemid 34579104)
22. Kunze KL and Trager WF (1993) Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem Res Toxicol 6:649-656. (Pubitemid 23290017)
23. Leung L, Kalgutkar AS, and Obach RS (2012) Metabolic activation in drug-induced liver injury. Drug Metab Rev 44:18-33.
24. Lewis DF and Lake BG (1996) Molecular modelling of CYP1A subfamily members based on an alignment with CYP102: rationalization of CYP1A substrate specificity in terms of active site amino acid residues. Xenobiotica 26:723-753. (Pubitemid 26233025)
25. Lightning LK, Jones JP, Friedberg T, Pritchard MP, Shou M, Rushmore TH, and Trager WF (2000) Mechanism-based inactivation of cytochrome P450 3A4 by L-754,394. Biochemistry 39:4276-4287. (Pubitemid 30212643)
26. Lin HL, Kenaan C, and Hollenberg PF (2012) Identification of the residue in human CYP3A4 that is covalently modified by bergamottin and the reactive intermediate that contributes to the grapefruit juice effect. Drug Metab Dispos 40:998-1006.
27. Liu H, Lightfoot R, and Stevens JL (1996) Activation of heat shock factor by alkylating agents is triggered by glutathione depletion and oxidation of protein thiols. J Biol Chem 271:4805-4812. (Pubitemid 26074965)
28. Lu P, Schrag ML, Slaughter DE, Raab CE, Shou M, and Rodrigues AD (2003) Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos 31:1352-1360. (Pubitemid 37310324)
29. Mitchell JR, Jollow DJ, Potter WZ, Davis DC, Gillette JR, and Brodie BB (1973) Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. J Pharmacol Exp Ther 187:185-194.
30. Moore CD, Reilly CA, and Yost GS (2010) CYP3A4-Mediated oxygenation versus dehydrogenation of raloxifene. Biochemistry 49:4466-4475.
31. Nelson SD (1982) Metabolic activation and drug toxicity. J Med Chem 25:753-765.
32. Pearson JT, Wahlstrom JL, Dickmann LJ, Kumar S, Halpert JR, Wienkers LC, Foti RS, and Rock DA (2007) Differential time-dependent inactivation of P450 3A4 and P450 3A5 by raloxifene: a key role for C239 in quenching reactive intermediates. Chem Res Toxicol 20:1778-1786.
33. Petrek M, Otyepka M, Banás P, Kosinová P, Koca J, and Damborský J (2006) CAVER: a new tool to explore routes from protein clefts, pockets and cavities. BMC Bioinformatics 7:316.
34. Requejo R, Chouchani ET, Hurd TR, Menger KE, Hampton MB, and Murphy MP (2010) Measuring mitochondrial protein thiol redox state. Methods Enzymol 474:123-147.
35. Romero FJ, Ordoñez I, Arduini A, and Cadenas E (1992) The reactivity of thiols and disulfides with different redox states of myoglobin. Redox and addition reactions and formation of thiyl radical intermediates. J Biol Chem 267:1680-1688.
36. Sansen S, Yano JK, Reynald RL, Schoch GA, Griffin KJ, Stout CD, and Johnson EF (2007) Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2. J Biol Chem 282:14348-14355. (Pubitemid 47100434)
37. Schoch GA, Yano JK, Sansen S, Dansette PM, Stout CD, and Johnson EF (2008) Determinants of cytochrome P450 2C8 substrate binding: structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid. J Biol Chem 283:17227-17237.
38. Shah MB, Pascual J, Zhang Q, Stout CD, and Halpert JR (2011) Structures of cytochrome P450 2B6 bound to 4-benzylpyridine and 4-(4-nitrobenzyl)pyridine: insight into inhibitor binding and rearrangement of active site side chains. Mol Pharmacol 80:1047-1055.
39. Silverman RB (1988) Mechanism-Based Enzyme Inactivation: Chemistry and Enzymology, CRC Press, Boca Raton, FL.
40. Stepan AF, Walker DP, Bauman J, Price DA, Baillie TA, Kalgutkar AS, and Aleo MD (2011) Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. Chem Res Toxicol 24:1345-1410.
41. VandenBrink BM and Isoherranen N (2010) The role of metabolites in predicting drug-drug interactions: focus on irreversible cytochrome P450 inhibition. Curr Opin Drug Discov Devel 13:66-77.
42. Wen B, Doneanu CE, Gartner CA, Roberts AG, Atkins WM, and Nelson SD (2005) Fluorescent photoaffinity labeling of cytochrome P450 3A4 by lapachenole: identification of modification sites by mass spectrometry. Biochemistry 44:1833-1845. (Pubitemid 40223615)
43. Wester MR, Yano JK, Schoch GA, Yang C, Griffin KJ, Stout CD, and Johnson EF (2004) The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-A resolution. J Biol Chem 279:35630-35637. (Pubitemid 39100565)
44. Wienkers LC and Heath TG (2005) Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 4:825-833. (Pubitemid 41553963)
45. Yano JK, Wester MR, Schoch GA, Griffin KJ, Stout CD, and Johnson EF (2004) The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-A resolution. J Biol Chem 279:38091-38094. (Pubitemid 39295952)
46. Yu L, Liu H, Li W, Zhang F, Luckie C, van Breemen RB, Thatcher GR, and Bolton JL (2004) Oxidation of raloxifene to quinoids: potential toxic pathways via a diquinone methide and o-quinones. Chem Res Toxicol 17:879-888. (Pubitemid 38955346)
47. Yukinaga H, Takami T, Shioyama SH, Tozuka Z, Masumoto H, Okazaki O, and Sudo K (2007) Identification of cytochrome P450 3A4 modification site with reactive metabolite using linear ion trap-Fourier transform mass spectrometry. Chem Res Toxicol 20:1373-1378. (Pubitemid 350057206)